Amarin Claims ‘Little Impact’ From Teva’s US Vascepa Generic
Originator Aware Of Potential Fifth Launch From Zydus Cadila
“They have prescriptions just in the hundreds per week, which is in a market of 100,000 or so prescriptions a week,” Amarin has said of Teva’s Vascepa generic, the fourth to reach the US market.
